&w=3840&q=100)
Indian-origin professor Ganesh Thakur to lead Texas' top science academy
Indian-origin professor Ganesh Thakur has been named president of the Texas Academy of Medicine, Engineering, Science and Technology (TAMEST), becoming the first University of Houston (UH) faculty member to hold the position.
Thakur, a professor of petroleum engineering at UH's Cullen College of Engineering, began his term in February, the university said in a release. He aims to raise the visibility of UH's research and promote collaboration across top institutions in Texas.
TAMEST brings together top minds from UH, UT Austin, Texas A&M, and others to tackle real-world challenges, Thakur said.
TAMEST includes 350 members of the US National Academies and eight Nobel laureates. Its next annual conference, focused on climate change, will be held in San Antonio in February 2026.
Thakur's term runs through 2027, during which he plans to position Houston as a national hub for science and innovation.
Ganesh's leadership will bring well-deserved attention to UH's faculty, said Cullen College Dean Pradeep Sharma.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
2 hours ago
- Time of India
Dr Reddy's, Alvotech to co-develop Keytruda biosimilar
Dr. Reddy's Laboratories and Alvotech are collaborating to develop, manufacture, and commercialize a biosimilar version of Keytruda, a highly successful cancer drug. This partnership aims to provide more affordable treatment options globally as Merck's patents begin to expire around 2028. The collaboration will enhance Dr. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Mumbai: Dr Reddy's Laboratories has entered into a collaboration with Reykjavik, Ireland-based biotech company Alvotech to co-develop, manufacture and commercialise a biosimilar version of blockbuster cancer drug Keytruda for the global (generic name is pembrolizumab ), manufactured and marketed by Merck & Co , is the most successful medicine, recording worldwide sales of $29.5 billion in 2024. It is used to treat multiple forms of the terms of the agreement, both companies will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs and responsibilities, Hyderabad-based DRL said in a statement on to certain exceptions, each party will have the right to commercialise the product traditional generics, which often face automatic patent infringement claims, biosimilars are developed more like original drugs, complete with clinical trials and patent disclosures, giving them a better chance of overcoming legal challenges. Also, Merck's core patents on pembrolizumab in the US are expected to start expiring around 2028.'This (collaboration) demonstrates our ability to develop and manufacture high quality and affordable treatment options for patients worldwide,' Erez Israeli, chief executive of DRL, said.Róbert Wessman, chairman and CEO of Alvotech, said, 'The agreement enables us to increase the availability of cost-effective, critical biologic medications to patients worldwide.'Keytruda is approved in the US to treat 40 cancers, unlike most medicines that treat a few indications or medical India, it is approved for use in 17 indications across 10 cancers or tumour types. Oncologists mostly prescribe it to treat certain types of lung cancers, followed by gastrointestinal cancer, triple-negative breast cancer and head and neck helps the body's immune system, which is the T-cells, to detect and fight cancer cells that hide and spread in organs.'Oncology has been a top focus therapy area for us, and this collaboration will enhance our capabilities in oncology, as pembrolizumab currently represents one of the most critical therapies in immuno-oncology ,' Israeli has been out of reach for most patients in India due to its exorbitant cost – roughly about Rs 2 lakhs for each dose. However, with Merck's patent set to expire in a few years and with Indian drug manufacturers looking to come up with more affordable versions of the drug it may play a crucial role in widening adoption across a larger cohort of patients.
India.com
3 hours ago
- India.com
India's Rs 548 crore Space Leap: Shukla rides the Falcon 9 to the ISS
On June 10, 2025, at 5:52 PM IST (8:22 AM EDT), Group Captain Shubhanshu Shukla will lift off to the International Space Station (ISS), becoming the first Indian astronaut since 1984 to undertake such a journey. As the pilot of Axiom Mission 4 (Ax-4), he will fly aboard a SpaceX Crew Dragon spacecraft, launched on a Falcon 9 rocket from NASA's Kennedy Space Center in Florida. After approximately 28 hours of travel, the crew is expected to dock with the ISS by 10:00 PM IST on June 11, 2025. Shukla joins an elite international crew: Commander Peggy Whitson (USA, Axiom Space), and Mission Specialists Sławosz Uznański-Wiśniewski (Poland, ESA) and Tibor Kapu (Hungary, Hunor Programme). The team will spend up to 14 days aboard the ISS, conducting over 60 scientific experiments from 31 countries, including seven from India, such as research on plant growth in microgravity, muscle regeneration, and tardigrade resilience. Born on October 10, 1985, in Lucknow, Shukla is a decorated Indian Air Force test pilot with over 2,000 flight hours. He has undergone rigorous astronaut training in Russia and at SpaceX facilities in the US, and will assist in spacecraft navigation, docking, and emergency procedures during the mission. But beyond his technical role, Shukla carries India's cultural pride into space—bringing along items designed by National Institute of Design (NID) students, performing yoga in microgravity, sharing Indian delicacies like mango nectar and moong dal halwa, and planning live interactions with Indian school children and possibly Prime Minister Narendra Modi. SpaceX has revolutionized space travel economics. While NASA pays around $55 million per seat under its commercial crew program, private clients like Axiom Space are charged $52–55 million per seat, excluding stay-related fees. NASA charges $35,000 per night per astronaut for use of the ISS. India's investment for Shukla's mission seat is around ₹548 crore (approximately $65 million), while the total private mission cost per astronaut can go up to $100 million, including training and logistics. In comparison, Russia's Soyuz costs around $80–86 million per seat, Boeing's Starliner costs about $90 million, and the now-retired Space Shuttle had a cost of approximately $170 million per astronaut. For reference, cargo missions on SpaceX's Dragon cost anywhere between $21,000 and $89,000 per kg, while human missions are far costlier due to added life support and safety systems. Shukla's mission is more than just a spaceflight—it's a symbol of India's return to human space exploration. He carries a special swan named 'Joy', representing wisdom (India), resilience (Poland), and grace (Hungary). The scientific experiments onboard are expected to contribute to India's ambition of establishing a space station by 2035 and support its moon mission goals set for 2047. This mission also strengthens international space ties, especially between India and the US, following commitments made during PM Modi's 2023 visit. In every sense, Group Captain Shubhanshu Shukla's journey aboard the human-rated Falcon 9 rocket is a giant leap for India—both in science and symbolism. With his successful flight, India not only rekindles its human spaceflight legacy after four decades but also sets the stage for greater roles in global space partnerships, cutting-edge research, and inspiration for the next generation of Indian scientists, engineers, and dreamers. —E.O.M (Girish Linganna is an award-winning science communicator and a Defence, Aerospace & Geopolitical is the Managing Director of ADD Engineering Components India Pvt. Ltd., a subsidiary of ADD Engineering GmbH, Germany )
India Today
4 hours ago
- India Today
IIT Mandi, Art of Living to advance research in consciousness, mental health
The Mind, Brain, and Consciousness Conference (MBCC 2025) opened to an intellectually vibrant start at the Indian Institute of Technology (IIT) Mandi on June 4. Organised by the Indian Knowledge System and Mental Health Applications (IKSMHA) Center, the four-day global event witnessed a confluence of neuroscientists, spiritual leaders, psychologists, philosophers, and AI researchers, marking a bold step in interdisciplinary research on consciousness and mental ON CONSCIOUSNESS AND INDIAN WISDOMMBCC 2025 (June 4–7) positions itself at the frontier of neuroscience, consciousness studies, mental well-being, and Indian philosophical traditions. The conference aims to foster dialogue across disciplines through research presentations, keynote addresses, workshops, and cultural programs, promoting the integration of Indian knowledge systems with cutting-edge scientific a significant move, IIT Mandi signed a Memorandum of Understanding (MoU) with the Art of Living Foundation, strengthening its commitment to collaborative research in consciousness and mental AND SCIENTIFIC THOUGHT LEADERS UNITE Sri Sri Ravi Shankar, spiritual leader and founder of the Art of Living Foundation, delivered a virtual keynote to open the event. Emphasising the role of spirituality in modern science, he remarked, 'Science now agrees that spirituality plays a vital role in mind and consciousness. Happiness is a concept of consciousness, nurtured through meditation, sattvic food, and pranayama.'advertisementProfessor Laxmidhar Behera, Director of IIT Mandi and General Chair of MBCC, highlighted the centrality of consciousness to both science and self-realisation. 'Without consciousness, the body is nothing. MBCC 2025 opens pathways for practical education, innovation, and interdisciplinary research rooted in Indian knowledge systems,' he Arnav Bhavsar, Chair of the IKSMHA Center, outlined the center's evolving research ecosystem, including the launch of a sleep research lab and collaborations with national institutions such as DRDO and the Ministry of Indologist Acharya Shrivatsa Goswami described the conference as a 'yagya of knowledge,' led by students and illuminated by the light of MBCC 2025 HAS IN STORE?The Mind, Brain, and Consciousness Conference (MBCC 2025) offers a rich academic and cultural programme. The four-day event features over 110 full paper presentations and 60 poster presentations by researchers from diverse fields. Attendees can participate in 12 thematic sessions covering topics such as cognitive biomarkers, neuroimaging, AI and consciousness, Ayurvedic psychiatry, and reincarnation conference also includes 4 keynote addresses and 3 plenary sessions featuring eminent speakers like Professor B N Gangadhar, Professor Gautam Desiraju, Professor Shrinivasa Varakedi, Professor Nirmalya Chakraborty, and HH Bhakti Rasamrita addition, there are 6 invited talks from leading scholars and 2 expert panel discussions focusing on Indian Knowledge Systems (IKS), cognition, and civilisational event offers hands-on learning experiences through 2 immersive workshops — one on Dharma in Indian Katha Parampara and another on Sattvic Cooking for Mental and Physical Health. Cultural programming includes 3 evenings of music, dance, and storytelling, exploring Indian traditions tied to MBCC 2025 continues until June 7, upcoming sessions will delve into crucial themes such as yoga and mental health, meditation and neurocognitive therapies, AI's intersections with consciousness, and the continuum of consciousness in Indian philosophical thought. This landmark event reaffirms IIT Mandi's growing role in interdisciplinary research, aiming to reshape how science engages with the human mind, consciousness, and holistic the full conference schedule and details, visit:
